[Federal Register Volume 66, Number 47 (Friday, March 9, 2001)]
[Notices]
[Pages 14153-14154]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-5812]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99E-1071]


Determination of Regulatory Review Period for Purposes of Patent 
Extension; Provigil

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) has determined the 
regulatory review period for Provigil and is publishing this notice of 
that determination as required by law. FDA has made the determination 
because of the submission of an application to the Commissioner of 
Patents and Trademarks, Department of Commerce, for the extension of a 
patent which claims that human drug product.

ADDRESSES: Submit written comments and petitions to the Dockets 
Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers 
Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Claudia V. Grillo, Regulatory Policy 
Staff (HFD-007), Food and Drug Administration, 5600 Fishers Lane, 
Rockville, MD 20857, 301-594-2041.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term 
Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug 
and Patent Term Restoration Act (Public Law 100-670) generally provide 
that a patent may be extended for a period of up to 5 years so long as 
the patented item (human drug product, animal drug product, medical 
device, food additive, or color additive) was subject to regulatory 
review by FDA before the item was marketed. Under these acts, a 
product's regulatory review period forms the basis for determining the 
amount of extension an applicant may receive.
    A regulatory review period consists of two periods of time: A 
testing phase and an approval phase. For human drug products, the 
testing phase begins when the exemption to permit the clinical 
investigations of the drug becomes effective and runs until the 
approval phase begins. The approval phase starts with the initial 
submission of an application to market the human drug product and 
continues until FDA grants permission to market the drug product. 
Although only a portion of a regulatory review period may count toward 
the actual amount of extension that the Commissioner of Patents and 
Trademarks may award (for example, half the testing phase must be 
subtracted as well as any time that may have occurred before the patent 
was issued), FDA's determination of the length of a regulatory review 
period for a human drug product will include all of the testing phase 
and approval phase as specified in 35 U.S.C. 156(g)(1)(B).
    FDA recently approved for marketing the human drug product Provigil 
(modafinil). Provigil is indicated to improve wakefulness in patients 
with excessive daytime sleepiness associated with narcolepsy. 
Subsequent to this approval, the Patent and Trademark Office received a 
patent term restoration application for Provigil (U.S. Patent No. 
4,177,290) from Cephalon, and the Patent and Trademark Office requested 
FDA's assistance in determining this patent's eligibility for patent 
term restoration. In a letter dated May 10, 1999, FDA advised the 
Patent and Trademark Office that this human drug product had undergone 
a regulatory review period and that the approval of Provigil 
represented the first permitted commercial marketing or use of the 
product. Later, the Patent and Trademark Office requested that FDA 
determine the product's regulatory review period.
    FDA has determined that the applicable regulatory review period for 
Provigil is 1,975 days. Of this time, 1,250 days occurred during the 
testing phase of the regulatory review period, while 725 days occurred 
during the approval phase. These periods of time were derived from the 
following dates:
    1. The date an exemption under section 505 of the Federal Food, 
Drug, and Cosmetic Act (the act) (21 U.S.C. 355) became effective: July 
30, 1993. FDA has verified the applicant's claim that the date the 
investigational new drug application became effective was on July 30, 
1993.
    2. The date the application was initially submitted with respect to 
the human drug product under section 505 of the act: December 30, 1996. 
FDA has verified the applicant's claim that the new drug application 
(NDA) for Provigil (NDA 20-717) was initially submitted on December 30, 
1996.
    3. The date the application was approved: December 24, 1998. FDA 
has verified the applicant's claim that NDA 20-717 was approved on 
December 24, 1998.
    This determination of the regulatory review period establishes the 
maximum potential length of a patent extension. However, the U.S. 
Patent and Trademark Office applies several statutory limitations in 
its calculations of the actual period for patent extension. In its 
application for patent extension, this applicant seeks 985 days of 
patent term extension.
    Anyone with knowledge that any of the dates as published is 
incorrect may submit to the Dockets Management Branch (address above) 
written comments and ask for a redetermination by May 8, 2001. 
Furthermore, any interested person may petition FDA for a determination 
regarding whether the

[[Page 14154]]

applicant for extension acted with due diligence during the regulatory 
review period by September 5, 2001. To meet its burden, the petition 
must contain sufficient facts to merit an FDA investigation. (See H. 
Rept. 857, part 1, 98th Cong., 2d sess., pp. 41-42, 1984.) Petitions 
should be in the format specified in 21 CFR 10.30.
    Comments and petitions should be submitted to the Dockets 
Management Branch. Three copies of any information are to be submitted, 
except that individuals may submit one copy. Comments are to be 
identified with the docket number found in brackets in the heading of 
this document. Comments and petitions may be seen in the Dockets 
Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

    Dated: February 16, 2001.
Jane A. Axlerad,
Associate Director for Policy, Center for Drug Evaluation and Research.
[FR Doc. 01-5812 Filed 3-8-01; 8:45 am]
BILLING CODE 4160-01-S